State-of-Art of Cellular Therapy for Acute Leukemia

State-of-Art of Cellular Therapy for Acute Leukemia

With recent clinical breakthroughs, immunotherapy has become the fourth pillar of cancer treatment. Particularly, immune cell-based therapies have been envisioned as a promising treatment option with curative potential for leukemia patients. Hence, an increasing number of preclinical and clinical st...

Full description

Bibliographic Details
Main Authors: Jong-Bok Lee, Daniel Vasic, Hyeonjeong Kang, Karen Kai-Lin Fang, Li Zhang
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:International Journal of Molecular Sciences
Subjects:
acute leukemia
adoptive cellular therapy
CAR-T cell
NK cell
DNT cell
Online Access:https://www.mdpi.com/1422-0067/22/9/4590
id doaj-011b45cd5a5247fe956b244e68569644
record_format Article
spelling doaj-011b45cd5a5247fe956b244e685696442021-04-28T13:22:28ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-04-01224590459010.3390/ijms22094590State-of-Art of Cellular Therapy for Acute LeukemiaJong-Bok Lee0Daniel Vasic1Hyeonjeong Kang2Karen Kai-Lin Fang3Li Zhang4Toronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, CanadaToronto General Hospital Research Institute, University Health Network, Toronto, ON M5G 1L7, CanadaWith recent clinical breakthroughs, immunotherapy has become the fourth pillar of cancer treatment. Particularly, immune cell-based therapies have been envisioned as a promising treatment option with curative potential for leukemia patients. Hence, an increasing number of preclinical and clinical studies focus on various approaches of immune cell-based therapy for treatment of acute leukemia (AL). However, the use of different immune cell lineages and subsets against different types of leukemia and patient disease statuses challenge the interpretation of the clinical applicability and outcome of immune cell-based therapies. This review aims to provide an overview on recent approaches using various immune cell-based therapies against acute B-, T-, and myeloid leukemias. Further, the apparent limitations observed and potential approaches to overcome these limitations are discussed.https://www.mdpi.com/1422-0067/22/9/4590acute leukemiaadoptive cellular therapyCAR-T cellNK cellDNT cell
collection DOAJ
language English
format Article
sources DOAJ
author Jong-Bok Lee
Daniel Vasic
Hyeonjeong Kang
Karen Kai-Lin Fang
Li Zhang
spellingShingle Jong-Bok Lee
Daniel Vasic
Hyeonjeong Kang
Karen Kai-Lin Fang
Li Zhang
State-of-Art of Cellular Therapy for Acute Leukemia
International Journal of Molecular Sciences
acute leukemia
adoptive cellular therapy
CAR-T cell
NK cell
DNT cell
author_facet Jong-Bok Lee
Daniel Vasic
Hyeonjeong Kang
Karen Kai-Lin Fang
Li Zhang
author_sort Jong-Bok Lee
title State-of-Art of Cellular Therapy for Acute Leukemia
title_short State-of-Art of Cellular Therapy for Acute Leukemia
title_full State-of-Art of Cellular Therapy for Acute Leukemia
title_fullStr State-of-Art of Cellular Therapy for Acute Leukemia
title_full_unstemmed State-of-Art of Cellular Therapy for Acute Leukemia
title_sort state-of-art of cellular therapy for acute leukemia
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-04-01
description With recent clinical breakthroughs, immunotherapy has become the fourth pillar of cancer treatment. Particularly, immune cell-based therapies have been envisioned as a promising treatment option with curative potential for leukemia patients. Hence, an increasing number of preclinical and clinical studies focus on various approaches of immune cell-based therapy for treatment of acute leukemia (AL). However, the use of different immune cell lineages and subsets against different types of leukemia and patient disease statuses challenge the interpretation of the clinical applicability and outcome of immune cell-based therapies. This review aims to provide an overview on recent approaches using various immune cell-based therapies against acute B-, T-, and myeloid leukemias. Further, the apparent limitations observed and potential approaches to overcome these limitations are discussed.
topic acute leukemia
adoptive cellular therapy
CAR-T cell
NK cell
DNT cell
url https://www.mdpi.com/1422-0067/22/9/4590
work_keys_str_mv AT jongboklee stateofartofcellulartherapyforacuteleukemia
AT danielvasic stateofartofcellulartherapyforacuteleukemia
AT hyeonjeongkang stateofartofcellulartherapyforacuteleukemia
AT karenkailinfang stateofartofcellulartherapyforacuteleukemia
AT lizhang stateofartofcellulartherapyforacuteleukemia
_version_ 1721503531790237696

Similar Items